HeartBeam Inc(BEAT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 7:53 PM ET (Korea 10/31 08:53)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.51 | Insider Own | 17.89% | Shs Outstand | 56.4M | Perf Week | 39.84% |
| Market Cap | 0.03B | Forward P/E | - | EPS next Y | 25.22% | Insider Trans | - | Shs Float | 46.3M | Perf Month | 31.26% |
| Enterprise Value | 0.02B | PEG | - | EPS next Q | -0.09 | Inst Own | 15.12% | Short Float | 5.37% | Perf Quarter | 11.83% |
| Income | -0.02B | P/S | - | EPS this Y | 38.17% | Inst Trans | 11.77% | Short Ratio | 0.34 | Perf Half Y | -37.63% |
| Sales | 0.00B | P/B | 3.79 | EPS next 5Y | 28.15% | ROA | -244.27% | Short Interest | 2.48M | Perf YTD | -77.08% |
| Book/sh | 0.15 | P/C | 3.55 | EPS past 3/5Y | 26.76% -36.66% | ROE | -328.44% | 52W High | -86.25% ($4.00) | Perf Year | -65.84% |
| Cash/sh | 0.15 | P/FCF | - | Sales past 3/5Y | - | ROIC | -248.21% | 52W Low | 54.93% ($0.35) | Perf 3Y | -51.33% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 26.8% | Gross Margin | - | Volatility(W/M) | 12.5% 12.44% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.05 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.61 | EPS Q/Q | 35.03% | Profit Margin | - | RSI (14) | 63.7 | Recom | 1.67 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.66 | Sales Q/Q | - | SMA20 | 18.41% ($0.46) | Beta | -0.78 | Target Price | $3.5 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/13 | SMA50 | 24.31% ($0.44) | Rel Volume | 0.2 | Prev Close | $0.54 |
| Employees | 16 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -16.28% -100% | SMA200 | -36.4% ($0.86) | Avg Volume(3M) | 7.28M | Price | $0.55 |
| IPO | 2021/11/11 | Option/Short | No/Yes | Trades | 1602 | Volume | 1,492,184 | Change | 2.06% |
🫀 HeartBeam () is a medical device company that has developed and commercialized a cable-free, 12-lead ECG synthesis device for home use. Its core technology is a patented method that measures cardiac electrical signals from three directions and synthesizes them into a 12-lead ECG.
Over the past 1 year, on the lower side
86% below its 1-year high.
Traded less than usual. That is 20% of its average volume.
BEAT has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +38.2% this year.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 3 years ago, your return today would be -51.3%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 15.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #32 of 41 in the industry
Based on market cap of $31M.
FAQ
What kind of company is BEAT?
BEAT belongs to the Healthcare sector and operates in the Health Information Services industry.
What is the market cap of BEAT?
The market cap of BEAT is approximately $31M, ranking 5,052 within its sector.
What is the 52-week high and low for BEAT?
BEAT has recorded a 52-week high of $4.00 and a low of $0.35.
